NEW MODEL: Jh mouse on B6 background Learn More

Press Releases

Taconic Biosciences Expands Scientific Advisory Board

Taconic Biosciences Expands Scientific Advisory Board

Dr. Monica Gostissa Joins Taconic Biosciences' Scientific Advisory Board Rensselaer, NY — March 15, 2021 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces Monica Gostissa, PhD, has joined its Scientific Advisory Board (SAB). Dr. Gostissa joins existing board members, Frank Sistare, PhD; Andrew Goodman, PhD; David Hill, PhD; and Robert Rosenthal, PhD. The SAB collaborates with Taconic management, providing scientific insight...  Read More

Taconic Biosciences Expands Immuno-oncology Animal Model Portfolio

Taconic Biosciences Expands Immuno-oncology Animal Model Portfolio

Critical Jh Syngeneic Tumor Model Host Now Available on a B6 Background Rensselaer, NY — January 18, 2021 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces an expansion of its immuno-oncology portfolio. Immuno-oncology is a leading research priority because it uses the body's own immune system to effectively treat some types of cancer. Syngeneic tumor animal models play a critical role...  Read More

Taconic Biosciences Expands Innovative ExpressMODEL® Portfolio

Taconic Biosciences Expands Innovative ExpressMODEL® Portfolio

New Random Integration Transgenic Animal Model Generation Solution Available Rensselaer, NY — December 3, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of the new ExpressMODEL®: Random Integration Transgenic (RITg) service, which reduces animal model generation costs and timeline. Many gene editing technologies are used to generate animal models for drug discovery, each with unique considerations but with...  Read More

Taconic Biosciences Launches Critical Model for COVID-19 Research

Taconic Biosciences Launches Critical Model for COVID-19 Research

Immediate availability of hACE2 mouse Rensselaer, NY — October 26, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces immediate humanized ACE2 mouse model availability for COVID-19 research. The SARS-CoV-2 virus, which causes COVID-19, uses the ACE2 receptor to enter cells. Due to differences between the mouse and human ACE2 receptors, normal laboratory mice cannot be infected with SARS-CoV2. Transgenic mice...  Read More

Taconic Biosciences to Distribute Critical COVID-19 Mouse Model

Taconic Biosciences to Distribute Critical COVID-19 Mouse Model

Signs Exclusive Agreement with University of Texas Medical Branch at Galveston to Access Humanized ACE2 Mouse Model Rensselaer, NY — June 22, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces an exclusive agreement with the University of Texas Medical Branch at Galveston (UTMB) to distribute humanized ACE2 mice for coronavirus research. The SARS-CoV-2 virus, which causes COVID-19, uses the ACE2...  Read More

Taconic Biosciences Expands Production of Critical Immunodeficient Model

Taconic Biosciences Expands Production of Critical Immunodeficient Model

Local Production of the CIEA NOG mouse® Model Now Available on the West Coast Rensselaer, NY, — June 10, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces local West Coast United States production of the immunodeficient CIEA NOG mouse® model. Immunodeficient animal models are critical to the drug discovery ecosystem. One of the most common contributors to the high product...  Read More

Taconic Biosciences Launches Rapid Restart™ Program

Taconic Biosciences Launches Rapid Restart™ Program

First Animal Model Provider to Create Program Aiding Researchers Planning for Return Rensselaer, NY, — May 18, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the successful implementation of its Rapid Restart™ program. Launched over a month ago, Taconic was the first animal model provider in the industry to provide researchers with a program specifically designed to aid laboratories transitioning...  Read More

Taconic Biosciences Supports Coronavirus Research

Taconic Biosciences Supports Coronavirus Research

Announces Preclinical COVID-19 Research Tools Rensselaer, NY — March 20, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces support for global COVID-19 research efforts via a new Coronavirus Toolkit featuring relevant models and services. Mouse models have been extensively used for research on the SARS-CoV virus, closely related to the new SARS-CoV-2 virus that causes COVID-19. Taconic offers many animal...  Read More

Taconic Biosciences Expands Humanized Mouse Model Production

Taconic Biosciences Expands Humanized Mouse Model Production

Local Production of Critical Immuno-oncology Models Now Available in Europe Rensselaer, NY — February 14, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces its humanized immune system mice models are now being produced in Europe. Local production provides European drug discovery researchers with easier access to this critical oncology research tool. Humanized immune system mice enable drug discovery research by...  Read More

Taconic Biosciences Launches New Immuno-oncology Mouse Model

Taconic Biosciences Launches New Immuno-oncology Mouse Model

Expands and Broadens Taconic Biosciences' Immuno-oncology Portfolio Application Rensselaer, NY — January 31, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, expands its premier immuno-oncology portfolio with the launch of the new B2m-NOG mouse model. Immuno-oncology leverages the body's immune system to fight cancer, increasing the ability to target the disease. Animal models used in this therapeutic development include special mice,...  Read More

Close

Welcome! Tell us a little about yourself